RayKnowChina Research Map
Shortlist

ShanghaiFudan University

Cancer Hospital, Fudan University

Listed for 1 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Cancer Hospital, Fudan University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Breast cancer乳腺癌0 papers led1 open trial led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Breast cancer

乳腺癌

Led no English-language PubMed papers on breast cancer in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
12
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution

19 hospitals in Shanghai for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06856200

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital, Fudan UniversityShanghai

  2. Recruiting
    A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07111832

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status16
  1. A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Lead (inferred)N/AStart 2025-02
  2. A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in ChinaStatus unknownNCT06591039Lead (inferred)Start 2022-07
  3. Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Lead (inferred)Phase 2Start 2020-05
  4. An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Status unknownNCT04395989Lead (inferred)Phase 2Start 2020-07
  5. Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingNCT04193059Lead (inferred)Phase 3Start 2019-12
  6. NX in Luminal B Breast Cancer Patients After Neoadjuvant ChemotherapyStatus unknownNCT04307147Lead (inferred)Phase 3Start 2018-07
  7. Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast CancerStatus unknownNCT03799679Lead (inferred)Phase 4Start 2018-11
  8. A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04297267Lead (inferred)Phase 2Start 2017-02
  9. Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast CancerCompletedNCT02980965Lead (inferred)Phase 3Start 2013-05
  10. Relationship Between Hypoxia and Endocrine Response in Human Breast CancerStatus unknownNCT01814449Lead (inferred)Start 2012-03
  11. Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast CancerStatus unknownNCT01170143Lead (inferred)Phase 2Start 2009-08
  12. Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast CancerStatus unknownNCT00525642Lead (inferred)Phase 2/Phase 3Start 2003-06
  13. A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast CancerRecruitingNCT07111832Study sitePhase 3Start 2025-08
  14. Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)Status unknownNCT03589924Study siteN/AStart 2018-06
  15. Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast CancerCompletedNCT03507088Study siteN/AStart 2015-09
  16. Ultrasound and Mammography for Screening Breast Cancer in Chinese WomenCompletedNCT01880853Study siteN/AStart 2008-11

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

Cancer Hospital, Fudan University

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
FUSCC ; Fudan University Shanghai Cancer Center

Suggest a correctionDownload the data